Introduction: Novel peroxisome proliferator-activated receptor (PPAR) modulators (selective
PPAR modulators [SPPARMs]) and dual PPAR agonists may have an important role in the …

Introduction: The fibrates have been used for many years to treat dyslipidemias and have
also recently been shown to have anti-inflammatory effects. They are relatively weak PPAR …

Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …

Non-alcoholic fatty liver disease (NAFLD) is a major health issue worldwide, frequently
associated with obesity and type 2 diabetes. Steatosis is the initial stage of the disease …

Dyslipidemia is a major risk factor for cardiovascular (CV) disease–the primary cause of
death, worldwide. Although reducing levels of low-density lipoprotein-cholesterol can …

The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic
steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the …

Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide. In addition to the liver-related morbidity and mortality, NAFLD is now also …

Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from
simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no …

Nonalcoholic fatty liver disease (NAFLD) is a general term for a series of liver diseases
including simple steatosis, non-alcoholic steatohepatitis, liver fibrosis, which is closely …

In the era of precision medicine, treatments that target specific modifiable characteristics of
high-risk patients have the potential to lower further the residual risk of atherosclerotic …